LEO LIN portrait
  • Assistant Professor (Clinical), Pathology
801-587-4281

Languages

  • English, Fluent.

Publications

  • Sorg RA, Lin L, van Doorn GS, Sorg M, Olson J, Nizet V, Veening JW (date unknown). Collective Resistance in Microbial Communities by Intracellular Antibiotic Deactivation. Vol. 14, e2000631. Accepted, .
  • Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, Barr JJ, Reed SL, Rohwer F, Benler S, Segall AM, Taplitz R, Smith DM, Kerr K, Kumaraswamy M, Nizet V, Lin L, McCauley MD, Strathdee SA, Benson CA, Pope RK, Leroux BM, Picel AC, Mateczun AJ, Cilwa KE, Regeimbal JM, Estrella LA, Wolfe DM, Henry MS, Quinones J, Salka S, Bishop-Lilly KA, Young R, Hamilton T (date unknown). Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection. Vol. 61. Accepted, .
  • Lin L, Sirohi D, Coleman JF, Gulbahce HE (date unknown). American Society of Clinical Oncology/College of American Pathologists 2018 Focused Update of Breast Cancer HER2 FISH Testing GuidelinesResults From a National Reference Laboratory. Vol. 152, 479-485. Accepted, .
  • Zare S, Lin L, Alghamdi AG, Daehne S, Roma AA, Hasteh F, Dell'Aquila M, Fadare O (date unknown). Comparative Pathologic Analysis of Breast Cancers Classified as HER2/neu-Amplified by FISH Using a Standard HER2/CEP17 Dual Probe and an Alternative Chromosome 17 Control Probe. Vol. 42, 1208-1215. Accepted, .
  • Huang YM, Miao Y, Munguia J, Lin L, Nizet V, McCammon JA (date unknown). Molecular dynamic study of MlaC protein in Gram-negative bacteria: conformational flexibility, solvent effect and protein-phospholipid binding. Vol. 25, 1430-7. Accepted, .
  • Hensler ME, Jang KH, Thienphrapa W, Vuong L, Tran DN, Soubih E, Lin L, Haste NM, Cunningham ML, Kwan BP, Shaw KJ, Fenical W, Nizet V (date unknown). Anthracimycin activity against contemporary methicillin-resistant Staphylococcus aureus. Vol. 67, 549-53. Accepted, .
  • Wyness SP, Lin L, Jensen R, Bird J, Norgyal T, Jensen G, Johnson LM (date unknown). Clinical and Analytical Verification of an Automated Fecal Calprotectin Immunoassay with Extraction Device. Vol. 6, 931-941. Accepted, .
  • Lin L, Kim J, Chen H, Kowalski R, Nizet V (date unknown). Component Analysis of Multipurpose Contact Lens Solutions To Enhance Activity against Pseudomonas aeruginosa and Staphylococcus aureus. Vol. 60, 4259-63. Accepted, .
  • van Sorge NM, Cole JN, Kuipers K, Henningham A, Aziz RK, Kasirer-Friede A, Lin L, Berends ETM, Davies MR, Dougan G, Zhang F, Dahesh S, Shaw L, Gin J, Cunningham M, Merriman JA, Hütter J, Lepenies B, Rooijakkers SHM, Malley R, Walker MJ, Shattil SJ, Schlievert PM, Choudhury B, Nizet V (date unknown). The classical lancefield antigen of group a Streptococcus is a virulence determinant with implications for vaccine design. Vol. 15, 729-740. Accepted, .
  • Lin L, Nonejuie P, Munguia J, Hollands A, Olson J, Dam Q, Kumaraswamy M, Rivera H Jr, Corriden R, Rohde M, Hensler ME, Burkart MD, Pogliano J, Sakoulas G, Nizet V (date unknown). Azithromycin Synergizes with Cationic Antimicrobial Peptides to Exert Bactericidal and Therapeutic Activity Against Highly Multidrug-Resistant Gram-Negative Bacterial Pathogens. Vol. 2, 690-8. Accepted, .
  • Kumaraswamy M, Lin L, Olson J, Sun CF, Nonejuie P, Corriden R, Döhrmann S, Ali SR, Amaro D, Rohde M, Pogliano J, Sakoulas G, Nizet V (date unknown). Standard susceptibility testing overlooks potent azithromycin activity and cationic peptide synergy against MDR Stenotrophomonas maltophilia. Vol. 71, 1264-9. Accepted, .
  • Lin L, Wyness SP, Jensen R, Bird J, Norgyal T, Jensen G, Johnson LM (date unknown). Comparison of Next-Generation Assays for Fecal Calprotectin vs the PhiCal Assay. Vol. 157, 252-256. Accepted, .
  • Zare SY, Lin L, Alghamdi AG, Daehne S, Roma AA, Hasteh F, Dell'Aquila M, Fadare O (date unknown). Breast cancers with a HER2/CEP17 ratio of 2.0 or greater and an average HER2 copy number of less than 4.0 per cell: frequency, immunohistochemical correlation, and clinicopathological features. Vol. 83, 7-13. Accepted, .
  • Lin L, Carlquist J, Sinclair W, Hall T, Lopansri BK, Bennett ST (date unknown). Experience With False-Positive Test Results on the TaqPath Real-Time Reverse Transcription-Polymerase Chain Reaction Coronavirus Disease 2019 (COVID-19) Testing Platform. (pp. 259-261). Vol. 145. Accepted, .